{
  "Variants Include": [
    {
      "Gene": "TP53",
      "variants": [
        {
          "HGVS": "NM_001126112.3:c.248G>A",
          "cDNA Change": {
            "transcript": "NM_001126112.3",
            "ref": "G",
            "alt": "A",
            "position": "248"
          },
          "Protein Change": {
            "ref": "G",
            "alt": "D",
            "position": "83"
          },
          "Description in input context": "This variant causes a structural change in the protein, affecting its function."
        },
        {
          "HGVS": "NM_001126112.3:c.255A>T",
          "cDNA Change": {
            "transcript": "NM_001126112.3",
            "ref": "A",
            "alt": "T",
            "position": "255"
          },
          "Protein Change": {
            "ref": "I",
            "alt": "M",
            "position": "85"
          },
          "Description in input context": "This variant affects protein stability and turnover."
        }
      ]
    }
  ],
  "Described Disease": {
    "Described Disease": "Hereditary Myopathy",
    "MONDO": "MONDO:0012345"
  },
  "Experiment Method": [
    {
      "Assay Method": "Western Blot",
      "Material used": {
        "Material Source": "Patient-Derived Fibroblasts",
        "Material Name": "Patient Fibroblasts",
        "Description": "Primary fibroblasts were obtained from patients diagnosed with Hereditary Myopathy and cultured according to standard protocols."
      },
      "Readout type": "Quantitative",
      "Readout description": [
        {
          "Variant": "NM_001126112.3:c.248G>A",
          "Conclusion": "Abnormal",
          "Molecular Effect": "partial loss-of-function",
          "Result Description": "Western blot analysis revealed a 50% reduction in protein levels for the c.248G>A variant compared to controls."
        },
        {
          "Variant": "NM_001126112.3:c.255A>T",
          "Conclusion": "Abnormal",
          "Molecular Effect": "increased protein turnover",
          "Result Description": "Western blot analysis with ubiquitin chase protocol showed increased protein turnover for the c.255A>T variant compared to controls."
        }
      ],
      "Biological replicates": {
        "Biological replicates": "Yes",
        "Description": "Each patient sample was analyzed in triplicate, representing three independent biological replicates."
      },
      "Technical replicates": {
        "Technical replicates": "Yes",
        "Description": "Each sample was run in triplicate on the Western blot apparatus for consistent measurements."
      },
      "Basic positive control": {
        "Basic positive control": "Yes",
        "Description": "Wild-type fibroblasts from a healthy donor were used as a positive control."
      },
      "Basic negative control": {
        "Basic negative control": "Yes",
        "Description": "Cells transfected with empty vector were used as a negative control."
      },
      "Validation controls P/LP": {
        "Validation controls P/LP": "Yes",
        "Counts": "2"
      },
      "Validation controls B/LB": {
        "Validation controls B/LB": "Yes",
        "Counts": "1"
      },
      "Statistical analysis method": {
        "Statistical analysis method": "ANOVA with post-hoc Tukey's test was used to assess statistical significance."
      },
      "Threshold for normal readout": {
        "Threshold for normal readout": "Protein levels within the range of 80-120% of the control group.",
        "Source": "Literature"
      },
      "Threshold for abnormal readout": {
        "Threshold for abnormal readout": "Protein levels outside the range of 80-120% of the control group with a p-value < 0.05.",
        "Source": "Literature"
      },
      "Approved assay": {
        "Approved assay": "Yes"
      }
    }
  ]
}